Soluble receptor activator of nuclear factor \( \kappa \)B ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients

Diana Carmona-Fernandes\( ^{1\dagger} \), Maria José Santos\( ^{1,2\dagger} \), Inês Pedro Perpêtu\( o \)\( ^{1} \), João Eurico Fonseca\( ^{1,3} \) and Helena Canhão\( ^{1,3\ast} \)

Abstract

Introduction: Systemic lupus erythematosus (SLE) patients have lower bone mineral density and increased fracture risk when compared with healthy individuals, due to distinct factors and mechanisms. Bone remodeling is a tightly orchestrated process dependent on several factors, including the balance between receptor activator of nuclear factor \( \kappa \)B ligand (RANKL) and osteoprotegerin (OPG). Our aim was to assess serum OPG and soluble RANKL (sRANKL) levels as well as sRANKL/OPG ratio in female SLE patients and compare it with female controls.

Methods: We have evaluated 103 SLE patients and 114 healthy controls, all Caucasian females. All participants underwent a clinical and laboratory evaluation. sRANKL and OPG were quantified in serum by ELISA based methods. sRANKL, OPG and sRANKL/OPG ratio levels were compared between SLE patients and age, sex and race matched healthy controls. For SLE patients, a multivariate analysis was performed, to find the possible predictors of the changes in sRANKL, OPG and sRANKL/OPG ratio levels.

Results: Although sRANKL levels did not differ between the two groups, serum OPG was lower in SLE patients (\( P < 0.001 \)). This led to an increased sRANKL/OPG ratio (\( P = 0.010 \)) in the patients’ group. The multivariate analysis was performed considering age and other clinical and laboratorial potential confounders for these variations in the SLE patients group. We have showed that age (\( P = 0.001 \)) and levels of anti-Sm antibodies (\( P = 0.016 \)) were independent predictors of sRANKL/OPG ratio variations in SLE patients. No relationship with therapy or disease activity measured by SLEDAI2K was found.

Conclusions: These results are suggestive of increased osteoclastic stimuli driven by the SLE disease mechanisms.

Keywords: sRANKL, osteoprotegerin, systemic lupus erythematosus, osteoclastogenesis

Introduction

Systemic lupus erythematosus (SLE) is a chronic, multi-systemic disease of unknown etiology characterized by chronic inflammation and damage to various organs and systems due to the production of autoreactive cells and antibodies [1-3].

SLE patients have lower bone mineral density (BMD) when compared with healthy individuals and are at increased risk of fracture [4-7]. Although corticosteroid exposure is a major contributor to bone loss in SLE [4,5,8], disease activity and associated co-morbidities may contribute to this process [5,8]. In addition, vitamin D deficiency is a common finding among SLE patients, further contributing to impaired bone health [5].

Bone remodeling is a tightly orchestrated process in which osteoclasts attach to the bone surface and remove bone. After resorption, osteoblasts migrate into the lacunae and produce new bone, which then mineralizes [3,9]. Expression of the receptor activator of nuclear factor \( \kappa \)B ligand (RANKL) by osteoblasts is essential to osteoclastogenesis. Osteoprotegerin (OPG) is a soluble...
receptor for RANKL that prevents RANK/RANKL interaction. Therefore, the RANKL/OPG ratio is critical for the control of bone resorption [10-12]. Increased RANKL/OPG ratio has been described in autoimmune diseases, such as rheumatoid arthritis, and was associated with an increased bone loss [7,13,14]. Taking these arguments into consideration, we have hypothesized that a RANKL/OPG imbalance is also present in SLE patients.

In the present work we aimed to assess the RANKL/OPG balance in SLE patients by quantifying serum OPG and sRANKL levels and their ratio in SLE patients and healthy controls. Additionally, in SLE patients we have looked at predictors of serum levels of these proteins and having as covariates disease features, co-morbidities and medications.

**Materials and methods**

**Patients**

Consecutive Portuguese Caucasian SLE women were recruited from the rheumatology outpatient clinics of Hospital de Santa Maria, Lisbon and Hospital Garcia de Orta, Almada, Portugal. All enrolled patients fulfilled the classification criteria of the American College of Rheumatology for SLE (1997) and had normal renal function defined as serum creatinine < 1.5 mg/dl. A control group matched to age, sex and race was also recruited, and was composed of healthy Caucasian female volunteers, who had not been diagnosed with SLE, nor had any inflammatory or bone disease and were not receiving corticosteroids or other medications known to interfere with bone metabolism. In this study, 103 SLE patients and 114 healthy controls were enrolled. This study was approved by the local Ethics Committees and all participants signed a written informed consent.

All participants underwent a standardized clinical and laboratory evaluation [15]. Information about age, height, weight, body mass index (BMI), smoking habits, alcohol intake, menopause, co-morbidities (hypertension, hyperlipidemia, diabetes mellitus, hypo or hyperthyroidism) and medication was collected.

For SLE patients, information considering age at disease diagnosis, disease duration, cumulative clinical manifestations, presence of autoantibodies, current disease activity (evaluated using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI2K) [16]), and cumulative damage (scored in accordance to the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SLICC) [17]) were also obtained.

**Laboratorial determinations**

A blood sample was collected from all subjects for measurement of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), lipids (total cholesterol, HDL, LDL and triglycerides), and anti-dsDNA and anti-Sm antibody titers.

Serum was obtained by blood centrifugation at 1,250 g, 4°C, at 4°C and then preserved at -80°C until use for sRANKL and OPG quantification.

sRANKL quantification was performed using the ampli sRANKL human ELISA (Immunodiagnostic Systems, Boldon, UK). OPG was quantified using the Bender MedSystems (Vienna, Austria) bead-based assay for quantitative detection of soluble human analytes by flow cytometry. Both protocols were performed according to the manufacturer’s instructions.

**Statistical analysis**

For statistical purposes samples undetectable or below the limit of detection (LOD) were considered to have the lower LOD value supplied by the manufacturer. Results were reported as means (standard deviation), medians (interquartile range) for continuous or proportions for categoric variables. sRANKL and OPG levels and sRANKL/OPG ratio were compared between SLE patients and healthy controls groups using the non-parametric Mann-Whitney test.

Subsequently, the impact of demographic parameters, clinical features, therapeutics and disease characteristics on these proteins and their ratio was investigated for SLE patients using univariate followed by multivariate linear regression analyses. All variables related to the studied outcome in univariate analyses at a P-value < 0.05 were considered potential predictors and entered in multivariate linear regression models. The selection of covariates was stepwise by backward selection, according to the level of significance. Before performing regression analysis, sRANKL, OPG, and sRANKL/OPG ratio were logarithmically transformed for approximation to normality and to approximate the residuals to the normality in multiple linear regressions.

Statistical calculations were performed using Statistical Package for the Social Sciences (SPSS) Statistics Software, v.15.0 (SPSS Inc., Chicago, USA) and a two-tailed P-value < 0.05 was selected as significant.

**Results**

A total of 103 SLE patients and 114 healthy controls with comparable baseline demographic characteristics and co-morbidities were studied (Table 1). SLE patients had a mean age at disease diagnosis of 35.6 ± 14.4 (range 9.0 to 80.0) years, 8.2 ± 6.6 (range 0.2 to 34.2) years of disease duration, a mean SLEDAI2K of 3.5 ± 4.5 (range 0 to 21) and a SLICC damage score of 0.8 ± 1.4 (range 0 to 8). A total of 60.2% of the patients were currently receiving corticosteroids in a mean daily dose of 12.7 mg.
Table 1 SLE patients and healthy controls characteristics

|                      | SLE patients | Healthy controls | P-value |
|----------------------|--------------|------------------|---------|
| n                    | 103          | 114              | -       |
| Age, years           | 44.9 ± 14.1  | 47.4 ± 13.5      | 0.182   |
| BMI, Kg/m²            | 26.6 ± 4.9   | 26.8 ± 4.9       | 0.689   |
| Current smokers, n (%)| 14 (15.6%)   | 23 (22.1%)       | 0.246   |
| Alcohol intake, n (%) | 4 (3.9%)     | 4 (3.6%)         | 0.602   |
| Postmenopausal, n (%) | 44 (49.4%)   | 57 (53.3%)       | 0.593   |
| Arterial hypertension, n (%) | 52 (50.5%) | 47 (42.7%) | 0.257   |
| Hyperlipidemia, n (%)  | 66 (64.1%)   | 66 (60.6%)       | 0.596   |
| Diabetes mellitus, n (%) | 5 (4.9%)   | 8 (7.2%)         | 0.472   |

Values represent mean ± standard deviation or frequencies of the individuals that presented the characteristic. Differences were assessed using T-test for continuous variables or χ² or Fisher’s exact test for proportions.

BMI, body mass index; SLE, Systemic Lupus Erythematosus

No significant differences were found between the two groups regarding sRANKL concentration. However, a statistically significant lower value was found for OPG levels in SLE patients (P < 0.001) compared to healthy controls. Consequently, an increase in sRANKL/OPG ratio (P = 0.010) was found in SLE patients compared to the healthy control group (Table 2).

The adjusted relationship between demographic parameters, clinical features, therapies and disease characteristics with sRANKL, OPG and sRANKL/OPG ratio was further analyzed in SLE patients (Table 3).

In univariate analysis, age, BMI, menopausal status, age at disease onset, the presence of malar rash, and anti-Sm and anti-dsDNA antibody quantifications were significantly associated with sRANKL levels. These possible predictors were included in a multivariate analysis and age (β = -0.232, 95% CI -0.043 to -0.004; P = 0.017), malar rash (β = 0.243, 95% CI 0.150 to 1.230; P = 0.013), and levels of anti-Sm antibodies (β = 0.227, 95% CI 0.005 to 0.051; P = 0.018) were identified as independent predictors of sRANKL levels in SLE patients.

The present work provides evidence of increased pro-osteoclastogenic stimuli in SLE women as a result of decreased serum OPG levels and increased sRANKL/OPG ratio.

OPG serum levels were lower in SLE patients than in controls and these levels were negatively associated with anti-dsDNA levels, independently from the contribution of multiple confounders. Raised anti-dsDNA levels are associated with active disease, suggesting that patients with active SLE might be more exposed to the effect of RANKL/RANK interaction as a consequence of diminished OPG levels. We have also found a positive association between serum OPG levels and diabetes mellitus, which is in accordance with previous results [18,19]. Gannagé-Yared and colleagues found an inverse correlation between OPG and triglycerides levels, in a nondiabetic, elderly Lebanese male population [20]. Although in a different population, this relation was not

Table 2 sRANKL, OPG and sRANKL/OPG ratio levels in SLE patients and healthy controls

|                      | SLE patients | Healthy controls | P-value |
|----------------------|--------------|------------------|---------|
| sRANKL               | 0.40 (0.02 to 25.99) | 0.40 (0.29 to 67.64) | 0.372   |
| OPG                  | 69.02 (17.42 to 500.90) | 95.14 (1.56 to 1069.13) | < 0.001|
| sRANKL/OPG ratio     | 0.0103 (0.0001 to 0.817) | 0.0056 (0.0001 to 1.866) | 0.010   |

Values represent median (IQR). Differences were assessed by non-parametric Mann-Whitney U test.

In 49.5% of SLE patients and 63.2% of healthy controls, the sRANKL levels were below the limit of detection (LOD) of the quantification method. Regarding OPG quantification, there were no samples with concentrations below the LOD.

IQR, interquartile range; OPG, osteoprotegerin; SLE, Systemic Lupus Erythematosus; sRANKL, soluble RANKL

Discussion

The present work provides evidence of increased pro-osteoclastogenic stimuli in SLE women as a result of decreased serum OPG levels and increased sRANKL/OPG ratio.

OPG serum levels were lower in SLE patients than in controls and these levels were negatively associated with anti-dsDNA levels, independently from the contribution of multiple confounders. Raised anti-dsDNA levels are associated with active disease, suggesting that patients with active SLE might be more exposed to the effect of RANKL/RANK interaction as a consequence of diminished OPG levels. We have also found a positive association between serum OPG levels and diabetes mellitus, which is in accordance with previous results [18,19]. Gannagé-Yared and colleagues found an inverse correlation between OPG and triglycerides levels, in a nondiabetic, elderly Lebanese male population [20]. Although in a different population, this relation was not
confirmed by our study, since we have found a positive relation between serum OPG and triglycerides.

Serum OPG levels have been scarcely analyzed in the context of SLE. There is a single study reporting higher serum OPG levels in SLE patients, and this relation is even greater in patients with antiphospholipid syndrome, as OPG levels were related to the presence of antiphospholipid antibodies [21]. This relation between OPG and these antibodies was not confirmed by us (data not shown).

On the other hand, urinary OPG levels have been described to be raised in lupus nephritis and correlated with renal disease activity and anti-dsDNA levels [22,23]. However, at this moment it is not clear how

Table 3 Predictors of sRANKL, OPG and sRANKL/OPG ratio levels in SLE patients (after multivariate analysis)

| Possible predictors       | Univariate analysis | Multivariate analysis‡ | Univariate analysis | Multivariate analysis§ | Univariate analysis | Multivariate analysis* |
|---------------------------|---------------------|------------------------|---------------------|------------------------|---------------------|------------------------|
|                           | β coefficient       | β coefficient          | β coefficient       | β coefficient          | β coefficient       | β coefficient          |
|                           | (95% CI)            | (95% CI)               | (95% CI)            | (95% CI)               | (95% CI)            | (95% CI)               |
|                           | P-value             | P-value                | P-value             | P-value                | P-value             | P-value                |
| Age                       | -0.304              | -0.232                 | 0.218               | -0.363                 | -0.326              | -0.058 to -0.019       |
|                           | (-0.049 to -0.12)   | (-0.043 to -0.004)     | (0.001 to 0.015)    | (-0.019)               | (-0.005 to -0.015)  |
|                           | 0.002               | 0.017                  | 0.027               | < 0.001                | 0.001               |
| BMI                       | -0.249              | 0.011                  | -0.211              | -0.123                 | 0.033               |
|                           | (-0.126 to -0.016)  |                        | (-0.123 to -0.005)  |                       |                     |
| Menopausal status         | -0.210              | 0.211                  | -0.274              | 0.009                  |
|                           | (-1.131 to -0.006)  | (0.003 to 0.439)       | (-1.379 to -0.200)  |                       |                     |
| Lipid lowering therapy    | 0.048               | 0.047                  |                    |                       |                     |
| Antihypertensive therapy  | 0.217               | 0.028                  | 0.271               | 0.247                  |
|                           | (0.026 to 0.438)    |                        | (0.198 to 1.122)    | (0.117 to 0.984)       |
| Diabetes mellitus         | 0.006               | 0.013                  |                    |                       |
|                           |                    |                        |                     |                       |
| Triglycerides             | 0.266               | 0.306                  | 0.211               | 0.274                  |
|                           | (0.000 to 0.003)    | (0.001 to 0.004)       | (0.003 to 0.439)    | (-1.379 to -0.200)    |
| Age at disease onset      | -0.268              | 0.237                  | -0.335              | 0.01                   |
|                           | (-0.045 to -0.008)  | (0.002 to 0.016)       | (-0.054 to -0.016)  |                        |
|                           | 0.006               | 0.016                  | 0.011               | 0.043                  |
| Malar rash                | 0.251               | 0.243                  | 0.201               | 0.019                  |
|                           | (0.166 to 1.246)    | (0.150 to 1.230)       | (0.109 to 1.178)    |                        |
| Arthritis                 | -0.272              | 0.005                  |                    |                       |
|                           | (-0.556 to -0.098)  |                        |                     |                       |
| Pleuritis                 |                    |                        |                     |                       |
| Anti-Sm titers            | 0.224               | 0.227                  | 0.264               | 0.229                  |
|                           | (0.003 to 0.051)    | (0.005 to 0.051)       | (0.009 to 0.059)    | (0.006 to 0.053)       |
|                           | 0.026               | 0.018                  | 0.008               | 0.016                  |
| Anti-dsDNA titers         | 0.204               | 0.268                  |                    |                       |
|                           | (0.000 to 0.007)    | (0.001 to 0.009)       |                     |                       |
|                           | 0.047               | 0.043                  | 0.016               | 0.009                  |

Multivariate analysis results from multiple linear regression analysis. The total explained variance of the model is (‡) R² = 0.185, (§) R² = 0.237, and (*) R² = 0.175.

OPG, osteoprotegerin; SLE, Systemic Lupus Erythematosus; sRANKL, soluble RANKL.
these results can be compared with ours as the relationship between serum and urinary OPG levels is unknown.

We have found sRANKL levels to be similar between SLE and healthy control women, but the sRANKL/OPG ratio was increased in SLE patients as compared to controls at the cost of elevated serum OPG levels in SLE. Interestingly, malar rash and elevated levels of anti-Sm autoantibodies, often present in active disease, were associated with sRANKL serum levels. Moreover, in multivariate analysis levels of anti-Sm antibodies were positively associated with sRANKL/OPG ratio. Studies based on sRANKL are sometimes limited by the high percentage of patients that have undetectable circulating levels, due to the fact that the majority of RANKL is membrane bound. Nevertheless, half of our patients had detectable levels of sRANKL and, importantly, it was possible to determine serum OPG levels in all individuals.

Despite the fact that there are no previous references in the literature to the possible effect of SLE on sRANKL and sRANKL/OPG ratio, an imbalance of this ratio has been described in autoimmune diseases, such as rheumatoid arthritis [13,24]. This finding may be of clinical relevance as the increase of the sRANKL/OPG ratio has been related with increased bone loss in immune mediated inflammatory diseases [12,25]. The independent association of the sRANKL/OPG ratio with anti-Sm autoantibodies and the absence of association with corticoid use or dose are particularly relevant, as they are suggestive that SLE per se might be important in accelerating osteoclastogenesis and consequently, bone loss.

Conclusions
In summary, we have shown reduced OPG levels and consequently a raised sRANKL/OPG ratio in female SLE patients as compared to healthy controls. An association between anti-dsDNA and OPG levels and between anti-Sm and sRANKL levels and sRANKL/OPG ratio were also observed in SLE patients. Taken together, these observations are suggestive of increased osteoclastic stimuli driven by SLE disease mechanisms.

Acknowledgements
This work was supported by a grant from Fundação para a Ciência e a Tecnologia, Portugal (PJC/IC/82920/2007) and by an unrestricted grant from Wyeth Portugal.

We wish to thank Dr. Vinagre F. from the Rheumatology Department at Hospital Garcia de Orta for helping with patients’ data collection and Dr. Caetano-Lopes J from the Rheumatology Research Unit at Instituto de Medicina Molecular for advice with statistical analysis.

Author details
1Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Edifício Egas Moniz, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal. 2Rheumatology Department, Hospital Garcia de Orta, Av. Torrado da Silva, 2801-951 Almada, Portugal. 3Rheumatology and Bone Metabolic Diseases Department, Hospital de Santa Maria, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal.

Authors’ contributions
DCF carried out laboratorial protein determinations and participated in the design of the study, statistical analysis and manuscript elaboration. MJL performed clinical evaluation of the patients and participated in the design of study, statistical analysis and manuscript elaboration. JPM helped on laboratorial protein determinations and on manuscript revision. JEF participated in the design of the study and on manuscript revision. HC participated in the design of the study and on manuscript and statistical analysis revision. All authors read and approved the final manuscript for publication.

Competing interests
The authors declare that they have no competing interests.

Received: 15 July 2011 Revised: 3 August 2011 Accepted: 25 October 2011 Published: 25 October 2011

References
1. Santos MJ, Vinagre F, Nero P, Barcelos F, Barcelos A, Rodrigues AM, de Matos AA, Silva C, Miranda L, Capela S, Marques A, Branco J, da Silva JC: Predictors of damage progression in Portuguese patients with systemic lupus erythematosus. Ann N Y Acad Sci 2009, 1173:822-828.
2. Garcia-Carrasco M, Mendoza-Pinto C, Escarcega RO, Jimenez-Hernandez M, Etchegary Moralés I, Munguia Realpozo P, Rebollo-Vázquez J, Soto-Vega E, Delezè M, Cervera R: Osteoporosis in patients with systemic lupus erythematosus. Isr Med Assoc J 2009, 11:486-491.
3. Lane NE: Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006, 2:562-569.
4. Lee C, Ramsey-Goldman R: Bone health and systemic lupus erythematosus. Curr Rheumatol Rep 2005, 7:482-489.
5. Alele JD, Kemen DL: The importance of inflammation and vitamin D status in SLE-associated osteoporosis. Autonmun Rev 2010, 9:137-139.
6. Weiss RJ, Wick MC, Ackermann PW, Montgomery SM: Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases – a case-control study with 53,108 patients with fracture. J Rheumatol 2010, 37:2247-2250.
7. Walsh NC, Crotti TN, Goldring SR, Gravallese EM: Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005, 208:238-251.
8. Panopalis P, Yazdany J: Bone health in systemic lupus erythematosus. Curr Rheumatol Rep 2009, 11:177-184.
9. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, Jones PB, Cornish J, McQueen FM: Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010, 12:R164.
10. Boyce BF, Xing L: Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007, 9:51.
11. Wright HL, McCarthy HS, Middleton J, Marshall MJ: RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009, 2:256-64.
12. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
13. Narducci P, Bareggi R, Nicolin V: Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology. Acta Histochem 2011, 113:73-81.

14. Caetano-Lopes J, Canhao H, Fonseca JE: Osteoimmunology—the hidden immune regulation of bone. Autoimmun Rev 2009, 8:250-255.

15. Silva C, Canhao H, Barcelos A, Miranda L, Pinto P, Santos MJ: Protocol for evaluation and monitoring of Systemic Lupus Erythematosus (PAMLES). Acta Reumatol Port 2008, 33:210-218.

16. Gladman DD, Ibanez D, Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.

17. Gladman D, Gader E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kallian J, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369.

18. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM: Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003, 149:39-42.

19. Browner WS, Liu LY, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86:631-637.

20. Ganne-Leray MH, Fares F, Semaan M, Khalife S, Jambart S: Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006, 64:652-658.

21. Kwok SK, Shin YI, Kim HJ, Kim HS, Kim JY, Yoo SA, Choi JJ, Kim WJ, Cho CS: Circulating osteoprotegerin levels are elevated and correlated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus 2009, 18:133-138.

22. Kiani AN, Johnson K, Chen C, Diehl E, Hu H, Vasudevan G, Singh S, Magder LS, Knecht CJ, Petri M: Urine osteoprotegerin and monocyte chemotactic protein-1 in lupus nephritis. J Rheumatol 2009, 36:2224-2230.

23. El-Shehaby A, Darweesh H, El-Khatib M, Momtaz M, Marzouk S, El-Shaarawy N, Emad Y: Correlations of Urinary Biomarkers, TNF-Like Weak Inducer of Apoptosis (TWEAK), Osteoprotegerin (OPG), Monocyte Chemotactic Protein-1 (MCP-1), and IL-8 with Lupus Nephritis. J Clin Immunol 2011, 31:848-856.

24. Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhao H, Resende C, Castelo A, Maceira C, Sequiera G, Sarafa F, da Silva JA, Carne-Fonseca M, Viana Queiroz M: Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol 2005, 23:165-192.

25. Khosla S: Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.

doi:10.1186/1478-6350
Cite this article as: Carmona-Fernandes et al.: Soluble receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. Arthritis Research & Therapy 2011 13:R175.